Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position
12:37am, Thursday, 05'th Jun 2025
I am bullish on CorMedix due to its strong financial turnaround, robust revenue growth, and unique market position. DefenCath, the only FDA-approved antimicrobial catheter lock solution in the US, dri
CorMedix: Exceeding Expectations
12:41pm, Wednesday, 04'th Jun 2025
CorMedix and its flagship product DefenCath have significantly outperformed expectations since commercialization, driving strong stock performance in 2025. DefenCath, approved just over a year ago, is
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference
08:30am, Friday, 30'th May 2025
BERKELEY HEIGHTS, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening d
CorMedix Inc. to Participate in the RBC Global Healthcare Conference
08:30am, Thursday, 15'th May 2025
BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening d
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock
01:20pm, Friday, 09'th May 2025
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript
11:59am, Tuesday, 06'th May 2025
CorMedix, Inc. (NASDAQ:CRMD ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Joe Todisco – Chief Executive Officer Matt David – Executi
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates
09:41am, Tuesday, 06'th May 2025
CorMedix (CRMD) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to loss of $0.25 per share a year ago.
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
07:30am, Tuesday, 06'th May 2025
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ.
CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025
08:30am, Tuesday, 29'th Apr 2025
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance
07:30am, Tuesday, 08'th Apr 2025
‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ BERKELEY HEIGHTS
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference
08:30am, Wednesday, 02'nd Apr 2025
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
An Investigation Has Commenced on Behalf of CorMedix Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CRMD Losses.
07:25am, Wednesday, 02'nd Apr 2025
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violati
CorMedix Inc. (CRMD) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
07:25am, Tuesday, 01'st Apr 2025
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violati
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violat
CorMedix: A Fair-Priced Biotech Company With A Bright Future
03:01am, Friday, 28'th Mar 2025
CorMedix Inc.'s DefenCath, FDA-approved in Q4 2023, effectively prevents catheter-related bloodstream infections in hemodialysis patients, showing 71% efficacy compared to competitors. Despite recent
